WO2017158480A1 - Nouveaux conjugués polysaccharide-protéine et procédé pour les obtenir - Google Patents

Nouveaux conjugués polysaccharide-protéine et procédé pour les obtenir Download PDF

Info

Publication number
WO2017158480A1
WO2017158480A1 PCT/IB2017/051408 IB2017051408W WO2017158480A1 WO 2017158480 A1 WO2017158480 A1 WO 2017158480A1 IB 2017051408 W IB2017051408 W IB 2017051408W WO 2017158480 A1 WO2017158480 A1 WO 2017158480A1
Authority
WO
WIPO (PCT)
Prior art keywords
polysaccharide
conjugates
protein
protein conjugates
activated
Prior art date
Application number
PCT/IB2017/051408
Other languages
English (en)
Inventor
Rakesh RANA
Juned DALAL
Manoj Kumar CHHIKARA
Davinder Gill
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.
Priority to BR112018068523A priority Critical patent/BR112018068523A2/pt
Priority to AU2017234319A priority patent/AU2017234319B2/en
Priority to CN201780017800.6A priority patent/CN108883192A/zh
Priority to MX2018010920A priority patent/MX2018010920A/es
Priority to JP2018548790A priority patent/JP2019508468A/ja
Priority to KR1020187027889A priority patent/KR102428253B1/ko
Priority to RU2018135066A priority patent/RU2758090C2/ru
Publication of WO2017158480A1 publication Critical patent/WO2017158480A1/fr
Priority to ZA2018/06043A priority patent/ZA201806043B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Definitions

  • the present invention relates to novel polysaccharide-protein conjugates and process to obtain thereof. More particularly, the present invention relates to polysaccharide - protein conjugates produced using carbamate chemistry capable of being used in production of monovalent vaccine or multivalent combination vaccines as well as a diagnostic tool. More specifically the present invention relates to Neisseria meningitidis serogroup X, A, C, Y and W135 polysaccharide-carrier protein conjugate using carbamate chemistry and the process to obtain the same.
  • N. meningitidis (meningococcus) is an aerobic gram-negative bacterium that has been serologically classified mainly into 13 serogroups A, B, Q D, 29E, H, I, K, L, W135, X, Y and Z.
  • the grouping system is based on the capsular polysaccharides of the organism. WHO official website mentions that N. meningitidis is o ne of the most common causes of bacterial meningitis in the world and the only bacterium capable of generating large epidemics of meningitis. Explosive epidemics with incidence rates of up to 1000 cases per 100,000 inhabitants have been reported, particularly in sub-Saharan Africa.
  • N. meningitidis is transmitted by aerosol or direct contact with respiratory secretions of patients or healthy human carriers. As a rule, endemic disease occurs primarily in children and adolescents, with highest attack
  • Haemophilus influenzae type b is a Gram-negative bacterium that causes meningitis and acute respiratory infections, mainly in children.
  • the WHO official website mentions that in both developed and developing countries, it is an important cause of non-epidemic meningitis in young children, and is frequently associated with severe neurological squeal, even if antibiotics are given promptly.
  • Haemophilus influenzae infection is transmitted by droplets from infected (but not necessarily symptomatic) people. H. influenzae type b infections can be prevented by vaccination.
  • meningococcal diseases are caused by 6 serogroups viz., A, B, C, Y, W135 and X. Historically, the majority of the cases in the meningitis belt are caused by serogroup A meningococci. Serogroup C meningococci were responsible for outbreaks in the meningitis belt in the 1980s, and a new outbreak was also experienced in Niger in 2015, while serogroup W (formerly W-135) has emerged as a cause of epidemic meningitis since 2000. Serogroup Y prevalence is minimal in Africa; however, the serogroup is more evident in meningitis cases in South America.
  • Serogroup X meningococci have previously been considered a rare cause of sporadic meningitis, but during 2006-2010, outbreaks of serogroup X meningitis occurred in Niger, Kenya, Togo and Burkina Faso, the latter with at least 1300 cases of serogroup X meningitis among the 6732 reported cases.
  • serogroup X meningococci accounted for 16% of the 702 confirmed bacterial meningitis cases.
  • Kozah district experienced a serogroup X meningococci outbreak in March 2007 with a serogroup X meningococci seasonal cumulative incidence of 33/100,000.
  • serogroup X meningococci accounted for 7% of the 778 confirmed bacterial meningitis cases, with an increase from 2009 to 2010 (4% to 35% of all confirmed cases, respectively).
  • the reaction of the polysaccharides with the CDI has been shown in several literature references.
  • the Carbonyldiimidazole a particularly preferred reagent, reacts with the hydro xyl groups to form imidazolylurethanes of the polysaccharide, and aryl chloroformates, including, for example, nitrophenyl- chloroformate, producing mixed carbonates of the polysaccharide.
  • the resulting activated polysaccharide is very susceptible to nucleophilic reagents, such as amines, and is thereby transformed into the respective urethanes.
  • nucleophilic reagents such as amines
  • polysaccharide protein conjugate vaccines can be made with or without a linker, wherein the linker can be a part of polysaccharide or can be attached to a carrier protein.
  • the existing state of art discloses vaccines for the treatment of various serogroups including Neisseria meningitidis serogroup A, B, C, W and Y such as the US patent application no US2015/ 0044253 which discloses the immunogenic composition comprising a saccharide fragment obtained from H. influenzae serotype B (Hib), N. meningitidis serogroup A, B, C, W, Y conjugated with a carrier protein.
  • Hib H. influenzae serotype B
  • N. meningitidis serogroup A, B, C, W, Y conjugated with a carrier protein.
  • the carbamate linker is linked directly onto amino groups of the carrier protein which results into low conjugation efficiency.
  • WO2004/ 019992 also discloses modified capsular saccharide, and saccharide protein conjugates for N. meningitidis serogroup A obtained by reductive amination, however, the application talks about the serogroup A only.
  • N. meningitidis serogroup X there are a fe disclosures available on N. meningitidis serogroup X such as WO2013/ 174832 which discloses conjugate of N. meningitidis serogroup X obtained by reductive amination conjugation chemistry.
  • the main object of present invention is to provide novel polysaccharide-protein conjugates.
  • Yet another object of the present invention is to provide a process to obtain said novel polysaccharide-protein conjugates using carbamate chemistry.
  • Yet another object of the present invention is to provide a process of rapid solubilization of the polysaccharide in non-aqueous aprotic solvents.
  • Yet another object of the present invention is to carry out the conjugation reaction in broader pH range.
  • the present invention provides novel polysaccharide (PS)- protein conjugates and process to obtain thereof. More particularly, the present invention relates to obtain the polysaccharide - protein conjugates by carbamate chemistry for the preparation of novel conjugate vaccines. More specifically the present invention relates to N. meningitidis serogroup X, A, C, Y and W135 polysaccharide-carrier protein conjugate using carbamate chemistry and the process to obtain the same. The present invention relates to the process of conjugation wherein capsular polysaccharide is degraded to smaller sizes suitable for conjugation with carrier protein to obtain conjugates with higher antigenicity.
  • PS polysaccharide
  • the carrier protein is selected from TT (tetanus toxoid), DT (Diphtheria toxoid), CRM197 (non-toxic mutant of DT), OMPV (Outer membrane protein vesicles) or other suitable carrier protein.
  • the polysaccharide fragment is obtained from group of gram negative bacteria, including but not limited to Haemophilus influenzae type b (Hib), Neisseria meningitidis (Men), Streptococcus pneumoniae.
  • the process of conjugation of Neisseria meningitidis capsular polysaccharide, more preferably Men A, C, Y, W or X capsular polysaccharide is degraded. Such degradation is carried out by using several techniques available in the prior art. More preferably, the degradation is carried out by probe sonication and/ or ultra-sonication at a lab scale and by micro fluidizer at larger scales.
  • the native N. meningitidis capsular polysaccharide is degraded in the size range of distribution coefficient of 0.38+0.06 kD as determined by gel-permeation chromatography (GPC) on high performance liquid chromatography (HPLC).
  • said degraded polysaccharide is dissolved in strong electrolytic salts for counter ion exchange, including but not limited to Lithium halides, Lithium chloride and Quaternary ammonium halide hydrates.
  • strong electrolytic salts for counter ion exchange including but not limited to Lithium halides, Lithium chloride and Quaternary ammonium halide hydrates.
  • the solution is allowed for proper mixing for 60 ⁇ 30 minutes.
  • Moisture is removed from the resultant capsular polysaccharide by any drying technique such as rotary-evaporation.
  • the dried capsular polysaccharide is then dissolved in the non-aqueous aprotic solvents including but not limited to anhydrous Dimethyl sulfoxide (DMSO), Dimethyl formamide (DMF), N-Methyl pyrrolidone (NMP) or Dimethyl Acetamide.
  • DMSO Dimethyl sulfoxide
  • DMF Dimethyl formamide
  • NMP N-Met
  • Said degraded and dried capsular polysaccharide in the non-aqueous aprotic solvent is reacted with 5-50 molar excess concentration of moisture free activating agents including but not limited to ⁇ , ⁇ '-Carbonyl Di imidazole (CDI), ⁇ , ⁇ '-Di- succinimidyl carbonate (DSC) or N,N'-Di-succinimidyl oxalate (DSO) and the mixture is kept in the presence of 4-dimethylaminopyridine (DMAP) or pyridine for pre-determined time to complete the reaction.
  • CDI ⁇ , ⁇ '-Carbonyl Di imidazole
  • DSC ⁇ , ⁇ '-Di- succinimidyl carbonate
  • DSO N,N'-Di-succinimidyl oxalate
  • the resultant activated capsular polysaccharide is purified by precipitating the polysaccharide in an excess of low polarity solvent including but not limited to ethyl acetate, dichloromethane, n-butyl acetate or their mixture in different proportions, followed by dissolving the precipitated polysaccharide in an aqueous buffer saline to obtain purified activated capsular polysaccharide.
  • low polarity solvent including but not limited to ethyl acetate, dichloromethane, n-butyl acetate or their mixture in different proportions
  • the purified activated capsular polysaccharide so obtained is dissolved in aqueous buffer with an activated carrier protein.
  • the activated carrier protein may be Carbohydrazide labelled or ADH labelled or Hydrazine labelled.
  • the solution of purified activated capsular polysaccharide and activated carrier protein is allowed for mixing at room temperature for predetermined period of time, preferably 15 ⁇ 5 hours at different pH range depending on whether the said polysaccharide is CDI activated, DSC activated or DSO activated.
  • the pH range for CDI activated polysaccharide is from 8-10, while the pH range for DSC activated or DSO activated polysaccharide is from 6-9.
  • the final conjugate with the formula PS-L1-L2-CR is produced, wherein PS is the polysaccharide, LI is a carbamate linkage, L2 is a hydrazide linkage and CR is the carrier protein.
  • the purified conjugates are obtained by the purification process including but not limited to ultrafiltration, ammonium sulphate precipitation, gel permeation chromatography.
  • the present invention also discloses the attaching of one linker preferably carbamate to the polysaccharide and second linker preferably hydrazine to the carrier protein, followed by reaction of activated polysaccharide and activated protein having separate linkers to generate a conjugate.
  • the present improved process of conjugation completes in shorter time span and yields conjugates of more stable covalent bond at wide working range of pH.
  • the novel polysaccharide-protein conjugate of the present invention displays more stability, high yield and high immunogenicity.
  • the present invention also discloses the method of dissolution of the polysaccharide in the non-aqueous aprotic solvent which facilitates conjugation reaction between the polysaccharide and the carbamate forming agent to complete the conjugation process in shorter time span.
  • the most significant outcome of the improved process of present invention is to provide novel polysaccharide-protein conjugates capable of being used in vaccine or as diagnostic tool.
  • the said novel polysaccharide- protein conjugate elicit specific and homologous immune response and is therefore useful in the production of monovalent vaccine or multivalent combination vaccines as well as a diagnostic tool.
  • FIG. 1 depicts the EDC (carbodiimide) cross-linking reaction scheme (R-
  • NH 2 is either Hydrazine (H2N-NH2) or Adipic Acid Dihydrazide
  • Figure 2 depicts the monomer unit of Men X capsular polysaccharide- chemical structure.
  • Figure 3 depicts the HPLC-SEC profile showing the elution volume on
  • Figure 4 depicts the HPLC-SEC profile comparison of native MenX polysaccharide with sized polysaccharides.
  • Figure 5 depicts the HPLC-SEC profile comparison of hydrazine derivatized TT with native TT.
  • Figure 6 depicts the Chromatogram showing purification of hydrazide derivatized TT on sephadex G25.
  • FIG. 7 depicts the Complete Carbamate Conjugation Scheme.
  • Figure 8 depicts the HPLC-SEC profile comparison of hydrazine derivatized TT with crude Men X Conjugate.
  • the present invention provides novel polysaccharide-protein conjugates and process to obtain thereof. More particularly, the present invention relates to obtain the chemically stable polysaccharide - protein conjugates by carbamate chemistry.
  • the polysaccharide fragment is obtained from group of gram negative bacteria, including but not limited to Haemophilus influenzae type b (Hib), Neisseria meningitidis (Men), Streptococcus pneumoniae, more preferably, N. meningitidis serogroups Men A, C, Y, W and preferably Men X.
  • the present invention also relates to obtain novel polysaccharide-protein conjugates with high immunogenicity capable of being used in vaccine individually or in combinations or as diagnostic tool.
  • the present invention also relates to the process of conjugation wherein said capsular polysaccharide is degraded to smaller sizes suitable for conjugation with carrier protein to obtain conjugates with higher antigenicity.
  • the present invention provides a process of conjugation using the CDI for hydroxyl group activation to form a polysaccharide-protein conjugates by a carbamate chemistry.
  • the carrier protein is selected from TT (tetanus toxoid), DT (Diphtheria toxoid), CRM197 (non-toxic mutant of DT), OMPV (Outer membrane protein vesicles) or other suitable carrier protein.
  • Said capsular polysaccharide is degraded by using several techniques available in the prior art. More preferably, the degradation is carried out by probe sonication and/ or ultra-sonication at a lab scale and by micro fluidizer at larger scales.
  • the native Neisseria meningitidis capsular polysaccharide is degraded in the size range of distribution coefficient of 0.38+0.06 kD.
  • the size of polysaccharide is determined by gel-permeation chromatography (GPC) on high performance liquid chromatography (HPLC).
  • said degraded polysaccharide is dissolved in strong electrolytic salts for counter ion exchange, including but not limited to Lithium halides, Lithium chloride and Quaternary ammonium halide hydrates.
  • strong electrolytic salts for counter ion exchange including but not limited to Lithium halides, Lithium chloride and Quaternary ammonium halide hydrates.
  • the solution is allowed for proper mixing for 60 ⁇ 30 minutes.
  • Moisture is removed from the resultant capsular polysaccharide by any drying technique such as rotary-evaporation.
  • the dried capsular polysaccharide is then dissolved in the non-aqueous aprotic solvents including but not limited to anhydrous Dimethyl sulfoxide (DMSO), Dimethyl formamide (DMF), N-Methyl pyrrolidone (NMP) or Dimethyl Acetamide.
  • DMSO Dimethyl sulfoxide
  • DMF Dimethyl formamide
  • NMP N-Meth
  • Said degraded and dried capsular polysaccharide in the nonaqueous aprotic solvent is reacted with 5-50 molar excess concentration of moisture free activating agents including but not limited to ⁇ , ⁇ '- Carbonyl Di imidazole (CDI), ⁇ , ⁇ '-Di-succinimidyl carbonate (DSC) or ⁇ , ⁇ '-Di-succinimidyl oxalate (DSO) and the mixture is kept in the presence of 4-dimethylaminopyridine (DMAP) or pyridine for predetermined time to complete the reaction.
  • CDI ⁇ , ⁇ '- Carbonyl Di imidazole
  • DSC ⁇ , ⁇ '-Di-succinimidyl carbonate
  • DSO ⁇ , ⁇ '-Di-succinimidyl oxalate
  • DMAP 4-dimethylaminopyridine
  • the Men PS has free hydroxyl group in its repeating unit, which when reacted to Carbonyl-
  • the resultant activated capsular polysaccharide is purified by precipitating the polysaccharide in an excess of low polarity solvent including but not limited to ethyl acetate, dichloromethane, n-butyl acetate or their mixture in different proportions, followed by dissolving the precipitated polysaccharide in an aqueous buffer saline to obtain purified activated capsular polysaccharide.
  • the carrier protein is reacted with water soluble carbodiimide EDC (N-(3- Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride) in the presence of Hydrazine or ADH to yield stable imide bonds with extending terminal hydrazide groups.
  • the EDC reacts with available carboxylate groups to form an intermediate, highly reactive, o-acylisourea. This active ester may further react with nucleophiles such as hydrazide to yield a stable final product (Fig 1).
  • the EDC cross-linking scheme (R-NH2) is either hydrazine or ADH. Carbonyls react with hydrazides and amines at pH 5-7.
  • the hydrolysis of EDC is a competing reaction during coupling and is dependent on temperature, pH and buffer composition.
  • the 4-Morpholinoethanesulfonic acid (MES) is an effective carbodiimide reaction buffer. Phosphate buffers reduce the reaction efficiency of the EDC, but increasing the amount of EDC can compensate for the reduced efficiency. Tris, glycine and acetate buffers may not be used as conjugation buffers.
  • the hydrazides labeling on TT is determined by TNBS assay; and the protein concentration is determined by Lowry's assay.
  • the degree of derivatization is calculated by dividing the moles of hydrazides generated by moles of protein.
  • the purified activated capsular polysaccharide so obtained is dissolved in aqueous buffer with an activated carrier protein.
  • the activated carrier protein may be Carbohydrazide labelled or ADH labelled or Hydrazine labelled.
  • the solution of purified activated capsular polysaccharide and activated carrier protein is allowed for mixing at room temperature for 15 ⁇ 5 hours at different pH range depending on whether the said polysaccharide is CDI activated, DSC activated or DSO activated.
  • the pH range for CDI activated polysaccharide is from 8-10, while the pH range for DSC activated or DSO activated polysaccharide is from 6-9.
  • the amine of the hydrazide moiety on the protein and -N- containing aromatic residue of carbamate or carbonate moiety on the activated polysaccharide reacts and results in the formation of polysaccharide-protein conjugate with stable carbamate linkage -O- (OO)-N-.
  • the final conjugate with the formula PS-L1-L2-CR is produced, wherein PS is the polysaccharide, LI is a carbamate linkage, L2 is a hydrazide linkage and CR is the carrier protein.
  • the purified conjugates are obtained by the purification process including but not limited to ultrafiltration, ammonium sulphate precipitation, gel permeation chromatography.
  • the conjugates prepared using carbamate chemistry has been tested to determine polysaccharide/ protein ratio, amount of free polysaccharide in the conjugates and molecular size distribution.
  • various optimization experiments have been conducted to attain the polysaccharide/ protein ratio in the range from 0.30 to 1.0 and the conjugation yields of upto 60% with an average of 30 ⁇ 5 % .
  • the Men PS derived from bacterial fermentation is purified by the downstream purification process and analyzed after purification for all the critical quality parameters.
  • the chemical structure of Men PS consists of repeating units with free hydroxyl group(s) e.g. MenX PS (Fig. 2) consists of repeat unit having a phosphate backbone and N-acetylation at position 3.
  • the hydroxyl groups at position no. 4 and 7 act as reactive functional groups for conjugation with carbamate inducing chemicals like CDI.
  • the monomer repeat units are called as monosaccharides and the long chain formed by a covalent bond in-between monosaccharide units, constitutes the Polysaccharide.
  • the monosaccharide type is specific for specific serogroup (Table 1).
  • the native Men PS have size range of distribution coefficient of 0.38+0.06 kD as determined by SEC on HPLC using pullulan standards.
  • the Carbamate chemistry of the present invention and the polysaccharide structure contributes for the formation of stable polysaccharide -protein conjugates to be used as a vaccine candidate either alone or in combination.
  • the content of degraded polysaccharide have been determined by physico- chemical assays e.g. phosphorus assay for MenX and MenA, and have been found to be similar to that of the initial polysaccharide content.
  • variable conditions have been used for he conditions varies for different batches depending upon the initial molecular size and structure of individual polysaccharide.
  • MenX Polysaccharide is degraded to smaller sizes suitable for conjugation with carrier protein to obtain conjugates with high antigenicity.
  • Tetanus toxoid (TT) is used as carrier protein.
  • Said degraded MenX polysaccharide is dissolved in Lithium chloride. The solution is allowed for proper mixing for a duration of 60 ⁇ 30 minutes. Moisture is removed from the resultant capsular polysaccharide by any known drying technique such as rotary- evaporation. The degraded and dried capsular polysaccharide is then dissolved in anhydrous Dimethyl sulfoxide (DMSO).
  • DMSO Dimethyl sulfoxide
  • the dried capsular polysaccharide in the non-aqueous aprotic solvent is reacted with 5-50 molar excess preferably 30 molar excess concentration of activating agent ⁇ , ⁇ '-Carbonyl Di imidazole (CDI), and the mixture is kept for mixing for a period of 2 hrs to 3 hrs to complete the reaction.
  • the pH of the reaction mixture is maintained at 7-10 preferably at 9.0.
  • the resultant activated MenX polysaccharide is purified by precipitating the polysaccharide in an excess of low polarity solvent ethyl acetate followed by dissolving the precipitated polysaccharide in an aqueous buffer saline to obtain purified activated capsular polysaccharide.
  • the linker is hydrazine or its derivative, attached to the carrier protein.
  • the sized active polysaccharide and the derivatized carrier protein are mixed in a proportion of 0.5:1 to 1:0.5 w/ w more preferably 1:1 w/ w in a buffer of pH 7.0-10.0 preferably 0.1M Sodium carbonate,01M NaCl, pH 9.0.
  • a buffer of pH 7.0-10.0 preferably 0.1M Sodium carbonate,01M NaCl, pH 9.0.
  • the amine of the hydrazide moiety on the protein and -N- containing aromatic residue of carbamate or carbonate moiety on the activated polysaccharide reacts and results in the formation of polysaccharide- protein conjugate with v e r y stable carbamate linkage -O- (OO)-N-.
  • the said conjugate is purified by known techniques and analyzed for total polysaccharide content, protein content, free polysaccharide, polysaccharide-protein ratio and conjugation yield.
  • the purified conjugates are stored 2 to 8°C.
  • the conjugates of the present invention are stable when exposed to high temperature conditions of 37°C. Men conjugates of the present invention show high antigenicity and high immunogenicity as revealed by serum bactericidal assay (SBA) and various immunogenic assays such as ELISA.
  • SBA serum bactericidal assay
  • ELISA immunogenic assay
  • Men X Polysaccharide is taken in a concentration at lOmg/ ml in glass beaker on ice bath. Run the sonicator at 20% amplitude for a time of 3 hrs.
  • the size of the degraded Polysaccharide is determined in terms of distribution coefficient (Kd) by running on HP-GPC (Table 2) using refractive index (RI) detector. Samples are eluted in 0.1 M NaN03 at pH 7.2 in isocratic mode on TSK gel G5000 PWXL + G4000 PWXL column in series. Elution volumes are measured in terms of retention time.
  • Void volume (V o) of the column is calculated from the high molecular weight dextran injection retention time and the total volume (V t) of the column is determined by sodium azide injection retention time respectively.
  • Ve is the retention time (RT) of elution volume of the sample (Fig. 3). The data recorded using RI detector shows the shift in peak towards right suggesting depolymerisation of native polysaccharides (Fig. 4).
  • 250 mg TT is concentrated using 50 kDa molecular weight cut off (MWCO) centrifugal filter to make final 10 ml.
  • MWCO molecular weight cut off
  • the 2.75ml of Hydrazine monohydrate from stock 5 M or 2.5gm of ADH, equivalent to 10X by weight of TT is added to 10 ml of reaction buffer i.e 0.15 M MES buffer containing 0.2 M NaCL pH 5.75 and added to TT above.
  • EDAC 250mg
  • the pH of the reaction mixture adjusted to 5.85 and final volume of the reaction mixture adjusted to 25 ml.
  • the concentration of TT in reaction mixture is 10 mg/ml.
  • the reaction mixture kept for slow stirring for 1.0 hour in ice bath.
  • the derivatized TT is further purified and analyzed for degree of activation and SEC-HPLC to monitor peak profile.
  • HPLC-SEC profile comparison of Hydrazine activated TT with native TT is shown in Fig 5 wherein the samples have been run on chromatography column in isocratic mode and the data have been recorded using PDA detector.
  • Purification is one of the most important steps in the process and in TT activation. We need to be sure to get rid of any un-reacted hydrazine or ADH to maximum possible.
  • the purification is done by Sephadex G-25 desalting method. Desalt the reaction mixture on sephadex G25 column against 50 mM phosphate buffer containing 75 mM NaCL pH 7.5 to purify the derivatized protein. Chromatography column equilibrated with 50 mM phosphate buffer containing 75 mM NaCL pH 7.5, followed by sample loading and elution at 110 cm/hr. Eluted fractions of 10 ml each collected and fractions corresponding to the peak at 280 nM on UV (Fig.
  • TT is pooled and concentrated by 50 kDa MWCO Amikon membrane. Selected fractions having TT are concentrated to such a volume to have TT concentration approximately 30-50 mg/ml (considering approximately 75% recovery of activated TT after desalting). Final activated TT is analyzed for protein concentration by Lowry assay and hydrazide labeling by TNBS assay. Both the values used for the calculation of degree of activation (DO A) of TT. Activated TT is run on HPLC at a concentration of 1 mg/ml using PWXL 5000 - PWXL 4000 columns in series to check the peak profile for its integrity.
  • the process of present invention activates the hydroxyl groups of the different polysaccharides preferably MenX PS with different activating agents preferably carbonyl di-imidazole to make it reactive towards the carrier protein to form a stable PS-TT conjugate (Fig 7).
  • Example 5 Conjugation reaction of activated MenX and derivatized TT
  • Derivatized TT has been added to the activated Men X PS directly in 3ml of 0.1M Sodium carbonate, 0.1M NaCl buffer at pH 9.0 solution and maintains the pH at 9.0.
  • Activated Polysaccharide and derivatized TT are mixed in a proportion of 1:1 w/w for the conjugation reaction. Formation of conjugate is confirmed in three hours of time only, but the crude conjugate mixture is kept mixing overnight at room temperature. The reaction is then quenched by using a 5-10 molar excess of amine-containing reagent such as glycine.
  • the course of conjugation is monitored by SEC-HPLC analysis with change in the retention time of the activated TT and peak shift towards the left.
  • HPLC-SEC profile of the conjugate depicts that conjugation reaction is completed to maximum within three to four hours.
  • the SEC-HPLC profiles of native and activated TT and the conjugate indicates that upon activation, the size of activated TT remains unchanged from the native TT, suggesting that little or no aggregation occurs.
  • the samples have been run on chromatography column at the flow rate of 1.0 ml/ min using 0.1M sodium nitrate, pH 7.2 buffer in isocratic mode and the data have been recorded using PDA detector.
  • crude conjugate is purified by protein precipitation method to remove free or unreacted polysaccharide. Purification is carried out by slowly adding solid ammonium sulphate to the reaction mixture until conjugate is precipitated out of the solution. The precipitates are separated by centrifugation at 5000 x g for 45 minutes. The supernatant is discarded and the precipitates re-dissolved in 30ml of 50 mM MES buffer containing 100 mM Nad, pH 6.5.
  • Example 7 Purification of polysaccharide-protein conjugate by Tangential flow filtration (TFF).
  • the conjugate sample after ammonium sulphate purification is further purified by using 300 kDa MWCO cassettes from Pall. This step ensures the removal of free protein if any from the conjugate and to separate free PS further from the conjugated PS.
  • the conjugate is diafiltered with 20 X volume of MES buffer, pH 6.5 and finally concentrated to a volume of 35 ml.
  • the purified conjugate is analyzed for total polysaccharide content by phosphorous assay for MenX-TT conjugates. Protein content is determined by Lowry's assay. The free polysaccharide determined by precipitating with sodium deoxycholate method and supernatant is analyzed by respective colorimetric assay. Different assays to determine the various residuals are conducted before using it further for formulation.
  • the purified conjugates are stored at 2 - 8 °C.
  • Conjugates of the present invention when analyzed for various 5 Quality parameters (Table 3) and found to give polysaccharide/ protein ratio in the range of 0.3 - 0.7 (w/w). Amount of free polysaccharide is different for different conjugates, however, over all free polysaccharide has been less than 10% in purified conjugates. Conjugation yield has also varied for different conjugates from 18% to 43% . In this invention, various 0 conjugation scales are tried from 20mg to 230mg.
  • Example 9 Characterization of Men A, C, Y, W conjugates obtained by carbamate chemistry
  • the Conjugates of the present invention are exposed to high temperature conditions of 37°C for 28 days.
  • the samples have been taken out on day 7,14,21 & 28 to monitor the free polysaccharide generated.
  • Table 5 Stability data for Men X-TT conjugate lot, prepared by the chemistry of present invention
  • Groups of 8 female BALB/c mice of 5-9 weeks have been immunized on days 0, 14 and 28 with two different lots of MenX conjugated PS antigen formulated in normal saline (Table 6) at 1 ⁇ g dose level. All immunizations are performed by administering 200 ⁇ of vaccine dilution via subcutaneous route. Normal saline alone is used for negative control group. Sera is collected at 7-14 days after 2 and 3-doses. Specific anti-PS IgG antibody titers are estimated by ELISA for post 2 and 3-dose.
  • Table 6 Geometric mean for IgG titer by ELISA post 2- and 3-dose (+,- 95% Confidence Interval for post 3-dose) for MenX-TT formulations in mouse model, after immunization with of antigen on day 0, 14 and 28.
  • Equal volume from each of the sera sample belonging to a group of mice are pooled together to make group sera pools for testing by serum bactericidal assay.
  • the assay is performed as follows:
  • the SBA data shows a negligible response from the vehicle immunizations after 3 doses, whereas both the Men X conjugate lots under test showed significantly high SBA titres as compared to the vehicle control indicating the vaccine to be effective in-vivo in the mouse model (Table 7).
  • Table 7 Geometric mean titer for SBA post 2- and 3-doses (+,- 95% Confidence Interval for post 3-doses) for MenX-TT formulations in mouse model, after immunization with of antigen on day 0, 14 and 28.

Abstract

La présente invention concerne de nouveaux conjugués polysaccharide-protéine, ainsi que le procédé d'obtention de ceux-ci. Plus particulièrement, la présente invention concerne des conjugués polysaccharide-protéine obtenus à l'aide de la chimie du carbamate, pouvant être utilisés dans la fabrication de vaccins monovalents ou de combinaison polyvalente de vaccins ainsi que comme outil de diagnostic. Plus précisément, la présente invention concerne un conjugué formé d'un polysaccharide de Neisseria meningitidis des sérogroupes X, A, C, Y et W135 et d'une protéine porteuse, et utilisant la chimie du carbamate, ainsi que le procédé d'obtention de celui-ci.
PCT/IB2017/051408 2016-03-15 2017-03-10 Nouveaux conjugués polysaccharide-protéine et procédé pour les obtenir WO2017158480A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR112018068523A BR112018068523A2 (pt) 2016-03-15 2017-03-10 novos conjugados de polissacarídeo-proteína e processo para obter os mesmos
AU2017234319A AU2017234319B2 (en) 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof
CN201780017800.6A CN108883192A (zh) 2016-03-15 2017-03-10 新型多糖-蛋白质结合物及其获取工艺
MX2018010920A MX2018010920A (es) 2016-03-15 2017-03-10 Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
JP2018548790A JP2019508468A (ja) 2016-03-15 2017-03-10 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法
KR1020187027889A KR102428253B1 (ko) 2016-03-15 2017-03-10 신규한 다당류-단백질 접합체 및 이의 제조방법
RU2018135066A RU2758090C2 (ru) 2016-03-15 2017-03-10 Новые конъюгаты полисахарида с белком и способ их получения
ZA2018/06043A ZA201806043B (en) 2016-03-15 2018-09-10 Novel polysaccharide-protein conjugates and process to obtain thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611008901 2016-03-15
IN201611008901 2016-03-15

Publications (1)

Publication Number Publication Date
WO2017158480A1 true WO2017158480A1 (fr) 2017-09-21

Family

ID=59851687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/051408 WO2017158480A1 (fr) 2016-03-15 2017-03-10 Nouveaux conjugués polysaccharide-protéine et procédé pour les obtenir

Country Status (9)

Country Link
JP (1) JP2019508468A (fr)
KR (1) KR102428253B1 (fr)
CN (1) CN108883192A (fr)
AU (1) AU2017234319B2 (fr)
BR (1) BR112018068523A2 (fr)
MX (1) MX2018010920A (fr)
RU (1) RU2758090C2 (fr)
WO (1) WO2017158480A1 (fr)
ZA (1) ZA201806043B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110652585A (zh) * 2018-10-26 2020-01-07 武汉博沃生物科技有限公司 多糖-蛋白缀合物免疫制剂及其制备与应用
EP3645045A4 (fr) * 2017-06-27 2021-03-31 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Nouvelle composition vaccinale multivalente à base de conjugués polysaccharide protéine et formulation de cette dernière
US11147866B2 (en) 2016-09-02 2021-10-19 Sanofi Pasteur Inc. Neisseria meningitidis vaccine

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041003A2 (fr) * 2009-06-22 2011-04-07 Wyeth Llc Compositions et procédés d'élaboration de compositions immunogènes conjuguées à polysaccharides capsulaires de sérotypes 5 et 8 de staphylococcus aureus
US20150044253A1 (en) * 2005-06-27 2015-02-12 Glaxosmithkline Biologicals S.A. Immunogenic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
RU2233172C2 (ru) * 1997-07-17 2004-07-27 Бакстэ Хелскеа С.А. Иммуногенный коньюгат полисахарид h. influenzae - порин менингококка группы b (варианты), способ его получения, фармацевтическая композиция и способ индукции иммунного ответа у животного в отношении h.influenzae
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN1709505B (zh) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
RU2634405C2 (ru) * 2012-01-30 2017-10-26 Серум Инститьют Оф Индия Лтд. Иммуногенная композиция
EP2870974A1 (fr) * 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044253A1 (en) * 2005-06-27 2015-02-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2011041003A2 (fr) * 2009-06-22 2011-04-07 Wyeth Llc Compositions et procédés d'élaboration de compositions immunogènes conjuguées à polysaccharides capsulaires de sérotypes 5 et 8 de staphylococcus aureus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHU , CHIAYUNG ET AL.: "Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates", INFECTION AND IMMUNITY, vol. 40, no. 1, 1983, pages 245 - 256, XP055422284 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147866B2 (en) 2016-09-02 2021-10-19 Sanofi Pasteur Inc. Neisseria meningitidis vaccine
US11707514B2 (en) 2016-09-02 2023-07-25 Sanofi Pasteur Inc. Neisseria meningitidis vaccine
EP3645045A4 (fr) * 2017-06-27 2021-03-31 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Nouvelle composition vaccinale multivalente à base de conjugués polysaccharide protéine et formulation de cette dernière
CN110652585A (zh) * 2018-10-26 2020-01-07 武汉博沃生物科技有限公司 多糖-蛋白缀合物免疫制剂及其制备与应用
CN110652585B (zh) * 2018-10-26 2023-05-26 武汉博沃生物科技有限公司 多糖-蛋白缀合物免疫制剂及其制备与应用

Also Published As

Publication number Publication date
MX2018010920A (es) 2019-03-06
JP2019508468A (ja) 2019-03-28
RU2758090C2 (ru) 2021-10-26
RU2018135066A (ru) 2020-04-06
RU2018135066A3 (fr) 2020-11-10
KR102428253B1 (ko) 2022-08-02
AU2017234319B2 (en) 2021-11-04
AU2017234319A1 (en) 2018-09-27
BR112018068523A2 (pt) 2019-01-22
ZA201806043B (en) 2019-05-29
CN108883192A (zh) 2018-11-23
KR20180121564A (ko) 2018-11-07

Similar Documents

Publication Publication Date Title
AU2017234319B2 (en) Novel polysaccharide-protein conjugates and process to obtain thereof
JP5361767B2 (ja) 水中において改善された安定性を持つ修飾糖
CN111065387B (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
ES2658851T3 (es) Vacunas de matriz de proteína y métodos de preparación y administración de tales vacunas
CN111093650B (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
ES2635488T3 (es) Sacáridos modificados
CN117736348A (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
TW201925458A (zh) 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
KR101266552B1 (ko) 그룹 ｙ 수막염균에 대한 백신 및 그의 수막염균성 조합
CN105828839B (zh) 沙门氏菌缀合物疫苗
JP7100031B2 (ja) 免疫原性コンジュゲート及びその使用
JP2019526573A (ja) ナイセリア・メニンギティディスのワクチン
ES2293002T5 (es) Vacunas de polisacárido y glucoconjugado mejoradas
US20110229513A1 (en) LPS Based Vaccines
WO2019198096A1 (fr) Composition de vaccin méningococcique tétravalente et son procédé de préparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/010920

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2018548790

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017234319

Country of ref document: AU

Date of ref document: 20170310

Kind code of ref document: A

Ref document number: 20187027889

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018068523

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17765940

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112018068523

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180912

122 Ep: pct application non-entry in european phase

Ref document number: 17765940

Country of ref document: EP

Kind code of ref document: A1